Skip to main content

CSL Media Statement on COVID19 Vaccine Manufacture

Development of the University of Queensland’s vaccine candidate remains CSL’s priority.

Media Statement

Development of the University of Queensland’s vaccine candidate remains CSL’s priority.

However, we are currently in discussions with AstraZeneca and the Australian Government to assess whether it is possible to provide local manufacturing support for the Oxford University/AstraZeneca vaccine, should it prove successful, while protecting our commitment to the UQ vaccine.

We are assessing the viability of options ranging from the fill and finish of bulk product imported to Australia through to manufacture of the vaccine candidate under licence.

There are a number of technical issues to work through and discussions are ongoing.

About CSL
CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 70 countries and employs 27,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information about CSL Limited, visit www.csl.com